2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2647

Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)
Abstract Number: 3225

Dual Cytokine Inhibition with ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain Immunoglobulin (DVD-Ig™): Results from a 24-Week Open-Label Extension Study in Patients with Rheumatoid Arthritis
Abstract Number: 481

Dual Effect of 3-Bromopyruvate on Both Th17 and Treg Cell Differentiation and Dendritic Cell Activation Ameliorates Autoimmune Arthritis in Mice
Abstract Number: 36

Dysautonomia and Osteoporosis in 2300 Ehlers-Danlos Hypermobile Patients, As Defined By the Brighton Criteria
Abstract Number: 73

Dysregulation of Hypomethylated Age-Related CpG Sites Characterize T-Cells and Monocytes from Treatment Naive Rheumatoid Arthritis Subjects
Abstract Number: 1841

Dysregulation of the Splicing Machinery Components in Leukocytes from Patients with Systemic Lupus Erythematosus: Influence on Autoimmune and Atherothrombotic Mechanisms
Abstract Number: 1555

E-Comorbidity: Evaluation of the Validity of Electronic Comorbidity Assessment in Identifying Comorbid Conditions Among Patients with Rheumatoid and Psoriatic Arthritis
Abstract Number: 2321

Early Damage and Mortality in a Cohort of Patients with Myositis Followed up to 20 Years
Abstract Number: 2472

Early DAS28 Drop Is a Predictor for Clinical Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis: An Observational Study of a Real Life Inception Cohort
Abstract Number: 489

Early Detection of Inflammatory Arthritis: The Role of Musculoskeletal Symptoms, Infections and Rheumatoid Arthritis-Related Comorbidities in Primary Care
Abstract Number: 1623

Early Effects of Tofacitinib on Bone Homeostasis in Patients with Rheumatoid Arthritis
Abstract Number: 1032

Early In Vivo Induction of Mouse Interferon-alpha1 Overexpression Triggers an Expansion of Highly Suppressive Regulatory T Lymphocytes Protecting Against Experimental Arthritis
Abstract Number: 115

Early Inflammatory Arthritis Presentation, Management and Outcomes in Canadian Aboriginal Patients
Abstract Number: 1457

Early Onset Morbidity and Mortality in Female Tumor Necrosis Factor Transgenic Mice with Inflammatory-Erosive Arthritis and Interstitial Lung Disease
Abstract Number: 1703

Early Onset of Efficacy with Apremilast Monotherapy in Biologic-Naive Patients with Active Psoriatic Arthritis: A Phase IIIb, Randomized, Controlled Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].